FGP
RAPP

Freestone Grove Partners’s Rapport Therapeutics RAPP Stock Holding History

Freestone Grove Partners’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-127,783
Closed -$4M – 1378
2026
Q1 		$4M Buy
+127,783
New +$3.59M 0.03% 337
2025
Q4 		– Sell
-45,130
Closed -$1.34M – 984
2025
Q3 		$1.34M Buy
+45,130
New +$805K 0.01% 407

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Freestone Grove Partners's RAPP Position: Q2 2026 in Review

Freestone Grove Partners sold out of Rapport Therapeutics (RAPP) in Q2 2026, closing a stake of 127,783 shares — an estimated $4M sold.

Freestone Grove Partners first reported a position in RAPP in Q3 2025 and held it in 2 quarters. The position peaked at $4M in Q1 2026. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Freestone Grove Partners reported no remaining Rapport Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 127,783 Rapport Therapeutics shares in Q2 2026, an estimated $4M.
  • Freestone Grove Partners first reported a position in Rapport Therapeutics in Q3 2025 and held it in 2 quarters.
  • Freestone Grove Partners's Rapport Therapeutics position peaked at $4M in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.